bioAffinity Technologies logo

bioAffinity Technologies(NASDAQ) BIAFW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-86%
5 YearN/A
1 Year-37%
1 Month+26%
$0.30
-47.10%
-0.27Today
bioAffinity Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.302026-10-13
bioAffinity Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-45.45%USD 0.552026-10-06
1 month+25.84%USD 0.242026-09-11
3 month+270.37%USD 0.082026-07-15
Year to date-14.29%USD 0.352025-12-31
1 year-36.72%USD 0.472025-10-13
3 year+114.59%USD 0.142023-10-13
Since inception-85.71%USD 2.102022-09-01

bioAffinity Technologies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.90M

Net Income (TTM)

-$15.19M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.30

Volume

3,265

Open

$0.54

Previous Close

$0.30

Daily Range

$0.27 - $0.56

52-Week Range

$0.05 - $0.98

Estimated Earnings Date

Nov 18, 2026

BIAFW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About bioAffinity Technologies

bioAffinity Technologies, Inc. is a pioneering company focused on developing non-invasive diagnostic laboratory tests for early-stage lung cancer and other lung diseases. Utilizing advanced flow cytometry and automated analysis, the company aims to improve patient outcomes through early detection and intervention.

Products and Services
  • CyPath lung test for early lung cancer detection
  • Flow cytometry technology for analyzing cell populations
  • Laboratory services for diagnostic research and development
Growth Outlook
  • Projected increase in lung cancer cases drives demand for early detection solutions
  • Expansion of laboratory services to enhance market reach
  • Strategic partnerships to accelerate product development and commercialization
Financial Highlights
  • Q2 2026 revenue of $1,510,579, showing growth from Q1
  • Cash and cash equivalents of $2,429,719 as of June 30, 2026
  • Current ratio of 1.44 indicates strong short-term financial health
bioAffinity Technologies, Inc. operates in the Medical - Diagnostics & Research industry and is headquartered in San Antonio, Texas. The company has made significant strides in developing innovative diagnostic solutions that address critical healthcare needs. With a focus on early detection of lung cancer, bioAffinity Technologies is positioned to capitalize on the growing demand for effective diagnostic tools. The recent quarterly performance reflects a positive trend in revenue, indicating potential for future growth. The company's financial health is supported by a solid current ratio, suggesting it can meet its short-term obligations effectively. As the healthcare landscape evolves, bioAffinity Technologies aims to play a crucial role in improving patient outcomes through its advanced diagnostic technologies.
AI Generated • Sep 20, 2026

Industry

Biotechnology

Headquarters

San Antonio, TX 78217, US

BIAFW Financials

Key Financial Metrics (TTM)

Gross Margin

-39.57%

Operating Margin

-209.82%

Net Income Margin

-257.33%

Return on Equity

-257.27%

Return on Capital

-125.29%

Return on Assets

-199.30%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

3.27K

Avg. Volume

5.88K

Financials (TTM)

Gross Profit

-$2.33M

Operating Income

-$12.38M

EBITDA

-$14.72M

Operating Cash Flow

-$11.47M

Capital Expenditure

-$31.41K

Free Cash Flow

-$11.50M

Cash & ST Invst.

$2.43M

Total Debt

$1.44M

bioAffinity Technologies Performance Analysis

bioAffinity Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.9%
Q42025-12-3110.1%
Q12026-03-31-15.1%
Q22026-06-3011.8%
bioAffinity Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.5%
Q42025-12-3161.6%
Q12026-03-3155.5%
Q22026-06-3021.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.51M

+19.0%

Gross Profit

-$3.33M

-1418.7%

Gross Margin

-2.21%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

57

N/A

Net Income

-$3.37M

+17.1%

EBITDA

-$3.29M

+15.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$2.43M

+202.6%

Total Debt

$1.44M

+114.2%

Accounts Receivable

$894.82K

+112.1%

Inventory

$82.38K

+87.3%

Long Term Debt

$1.17M

+261.0%

Short Term Debt

$265.43K

-23.3%

Return on Assets

-1.99%

N/A

Return on Invested Capital

-2.51%

N/A

Free Cash Flow

-$3.29M

-23.7%

Operating Cash Flow

-$3.20M

-20.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STRRStar Equity Holdings, Inc.
$9.99-6.98%
NOTVInotiv, Inc.
$0.08+121.94%
YI111, Inc.
$3.10-0.32%
PRPOPrecipio, Inc.
$22.59+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About BIAFW

What is the current price of bioAffinity Technologies?

bioAffinity Technologies is trading at $0.30 per share.

What is the 52-week range for bioAffinity Technologies?

Over the past 52 weeks, bioAffinity Technologies has traded between $0.05 and $0.98.

How much debt does bioAffinity Technologies have?

bioAffinity Technologies total debt is unavailable.

How much cash does bioAffinity Technologies have on hand?

bioAffinity Technologies does not have cash on hand data available.

What is bioAffinity Technologies’s dividend yield?

bioAffinity Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.